Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.

British journal of haematology - 1 Apr 2009

Lambert Jonathan R, Gale Rosemary E, Linch David C

Abstract excerpt

To clarify the relationship between the levels of JAK2 wild-type (WT) and V617F mutant-positive platelets in patients with essential thrombocythaemia (ET), we quantified mutant levels in purified cells from 10 V617F-positive patients prior to receiving cytoreductive therapy. Mutant levels were significantly higher in platelet than neutrophil RNA (P = 0.002), but the mutation was still only present in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Platelets
Share to Janus Kinase 2
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neutrophils

Share to Platelet Count

Share to Reverse Transcriptase Polymerase Chain Reaction

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 19222478
DOI: 10.1111/j.1365-2141.2009.07597.x

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.PMID 19222478Read ↗

JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.Semantic proximity Read ↗

In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm.Semantic proximity Read ↗

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia.Semantic proximity Read ↗

Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment.Semantic proximity Read ↗

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.Semantic proximity Read ↗

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.Semantic proximity Read ↗

JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.Semantic proximity Read ↗

Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.